10x Genomics, Cleveland Clinic launch bladder cancer biomarker study using single-cell, spatial platforms

10x Genomics

10x Genomics

TXG

0.00
  • 10x Genomics launched a multi-year research collaboration with Cleveland Clinic to develop diagnostic insights in advanced bladder cancer.
  • No clinical results were presented; the study will generate evidence in the future by linking molecular profiling with patient outcomes.
  • Work will analyze tumor samples from patients receiving antibody-drug conjugates or immunotherapy to find biomarkers tied to treatment response or resistance.
  • Study uses Flex Apex, Xenium, with potential expansion to Atera, positioning the platforms for future oncology diagnostic development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA85566) on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.